18.55k followers • 14 symbols Watchlist by TREA
Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.
Curated by TREA
|Watchlist||Change today||1-month return||1-year return||Total return|
|The Fight Against COVID19||+2.11%||-||-||-|
|Symbol||Company name||Last price||Change||% change||Market time||Volume||Avg vol (3-month)||Market cap|
|JNJ||Johnson & Johnson||170.48||+4.50||+2.71%||4:00 pm GMT-5||13.97M||7.73M||448.80B|
|PFE||Pfizer Inc.||37.31||+0.03||+0.08%||4:02 pm GMT-5||26.94M||46.96M||207.38B|
|ABBV||AbbVie Inc.||108.8||-1.70||-1.54%||4:02 pm GMT-5||5.41M||8.20M||192.01B|
|SNY||Sanofi||49.15||-0.48||-0.97%||4:00 pm GMT-5||2.59M||1.93M||123.69B|
|GSK||GlaxoSmithKline plc||39.24||+0.32||+0.82%||4:00 pm GMT-5||3.82M||4.93M||97.53B|
|GILD||Gilead Sciences, Inc.||66.7||-1.46||-2.14%||4:00 pm GMT-5||6.96M||9.38M||83.61B|
|MRNA||Moderna, Inc.||151.85||+4.85||+3.30%||4:00 pm GMT-5||16.96M||23.97M||60.09B|
|REGN||Regeneron Pharmaceuticals, Inc.||544.1||-4.10||-0.75%||4:00 pm GMT-5||901.68k||934.88k||58.06B|
|TAK||Takeda Pharmaceutical Company Limited||18.18||-0.19||-1.03%||4:00 pm GMT-5||9.05M||2.50M||56.98B|
|BNTX||BioNTech SE||106.29||-4.32||-3.91%||4:00 pm GMT-5||3.82M||4.09M||25.59B|
|VIR||Vir Biotechnology, Inc.||77.38||+32.99||+74.32%||4:00 pm GMT-5||11.52M||1.19M||9.86B|
|NVAX||Novavax, Inc.||127.16||-4.30||-3.27%||4:00 pm GMT-5||2.25M||4.12M||8.55B|
|INO||Inovio Pharmaceuticals, Inc.||10.58||+0.86||+8.85%||4:00 pm GMT-5||17.79M||11.54M||2.16B|
Johnson and Johnson expects vaccine data next week.
Sanofi said it would manufacture the Pfizer vaccine. And Johnson & Johnson could receive authorization for its single-dose vaccine in the coming weeks.
Shares of Regeneron Pharmaceuticals Inc. gained 1.2% in premarket trading on Wednesday after the company said its COVID-19 antibody cocktail still works against two new more infectious strains of the virus: the B.1.1.7 and the B.1.351. The company worked with researchers at Columbia University to assess how the drug, which has received emergency authorization in the U.S., works against the new strains in a laboratory, according to a preprint published Wednesday. (A preprint is a type of preliminary study.) The study was not conducted in humans. Regeneron said its antibody cocktail, made up of imdevimab and casirivimab, remained effective against the B.1.1.7 strain, but casirivimab's potency was reduced against the B.1.351 strain, which was first identified in South Africa. It has not yet tested the cocktail against the P.1 strain that has emerged from Brazil. Close to 300 people in the U.S. have confirmed cases with the B.1.1.7 strain, which was first detected in the United Kingdom, and the first case of P.1. in the U.S. was identified this week in Minnesota. The B.1.351 has not yet been detected in the U.S. BioNTech SE /Pfizer Inc. and Moderna Inc. also ran similar studies evaluating if their vaccines can protect against the new variants. Regeneron's stock has rallied 60.3% over the past year, while the S&P 500 is up 16.8%.